Global contract research organization (CRO) Worldwide Clinical Trials has entered into a definitive agreement to acquire Catalyst Clinical Research. The move is designed to establish a premier oncology-focused organization capable of delivering end-to-end clinical development solutions globally.
Synergizing expertise with global reach The acquisition bridges Catalyst’s specialized expertise in early-phase oncology with Worldwide’s established strengths in late-phase development. This strategic alignment creates a differentiated CRO that maintains deep therapeutic knowledge across multiple sectors while positioning oncology as a core pillar.
Strategic highlights of the acquisition:
-
Enhanced Service Models: Catalyst’s two primary offerings, Catalyst Oncology and Catalyst Flex, will integrate into Worldwide’s portfolio, providing clients with full-service, Functional Service Provider (FSP), and hybrid resourcing solutions.
-
Technological Integration: The combined entity aims to leverage advanced business management tools and AI to drive operational excellence, enhancing speed and data transparency throughout the clinical trial lifecycle.
-
Leadership Transition: Catalyst CEO Nik Morton will join Worldwide’s executive leadership team, and Nick Dyer, Chairman of Catalyst, will be appointed to the Worldwide Board of Directors.
Financial and operational outlook While the financial terms remain undisclosed, the transaction is backed by private equity firms Kohlberg (for Worldwide) and QHP Capital (for Catalyst). The deal is expected to close within the first quarter of 2026. Post-merger, Worldwide will command an expanded global footprint spanning over 60 countries with a combined workforce of more than 4,500 employees.